J&J’s nearly $17 billion offer to buy a heart pump maker goes right to why we own it

Health, Fitness & Food

Johnson & Johnson headquarters in New Brunswick, N.J.
Mel Evans | AP

Johnson & Johnson‘s (JNJ) $16.6 billion deal to buy heart pump maker Abiomed (ABMD) will bolster its pharmaceutical and medical device business ahead of J&J’s plans to separate its consumer division into a separate company. The Abiomed acquisition is set to close at the end of the first quarter of 2023. The spin-off of J&J’s consumer business, including such brands as Band-Aid and Tylenol, is expected in November of next year.

Articles You May Like

How Alarming Is This Year’s Flu Season?
Despite ongoing Covid risks, more employees consider cutting back on health-care benefits
A New Look to Better Serve Our Asthma and Allergy Community
The prevalence and risk factors of pediatric post-COVID in a population-based sample
High Neuro Drug Costs Exclude Most From Cutting-Edge Tx

Leave a Reply

Your email address will not be published. Required fields are marked *